228 results about "Esophageal squamous cell carcinoma" patented technology

The invention relates to an application of an esophageal squamous cell carcinoma primary tumor strain CH-H-1 in a mammal for producing esophageal squamous cell carcinoma cells. The primary tumor strain CH-H-1 disclosed by the invention can realize multiple passages through NOD / SCID mice, has significance for solving the bottleneck that the current treatment of the esophageal squamous cell carcinoma can not avoid distant metastasis, and is an ideal object for fundamental research on the esophageal squamous cell carcinoma and clinical early application.

The invention belongs to the technical field of medical oncology, and particularly discloses an autoantibody joint detection ELISA kit for early screening of esophageal squamous carcinoma. The kit comprises a solid-phase carrier and a tumor-associated antigen coated on the solid-phase carrier, wherein the tumor-associated antigen consists of P53, TP53, CDKN2B and NPM1. Furthermore, the kit comprises sample diluent, a second antibody, second antibody diluent, positive control serum, negative control serum, developing solution, stop solution and washing solution. The ELISA kit is capable of effectively detecting the esophageal squamous carcinoma, especially the early esophageal squamous carcinoma, has detection sensitivity up to 88.8% and specificity up to 86.3%, can be used for the large-scale screening of asymptomatic groups in high-risk areas of the esophageal squamous carcinoma, and is beneficial for the esophageal squamous carcinoma screening and early discovery of the asymptomatichigh-risk groups.

The invention relates to the field of bioengineering and tumor markers, in particular to a marker for locally advanced esophageal squamous cell carcinoma prognosis and an application of the marker. The marker is a combined marker consisting of one or more of miR-135b-5p, miR-139-5p, miR-29c-5p and miR-338-3p, and locally advanced esophageal squamous cell carcinoma prognosis is predicted by detecting expression levels of the four miRNA in tumor tissue and performing calculation according to a formula (0.4690*miR-135b-5p expression level)+(0.3839*miR-139-5p expression level)+(0.1733*miR-29c-5p expression level)+(0.3368*miR-338-3p expression level). The combined marker has the advantages of good stability and high sensitivity and specificity and can more accurately and more valuably evaluateprognosis of patients than traditional clinical pathological factors such as TNM (tumor-node-metastasis) staging and the like. On one hand, the molecular marker related to esophageal squamous cell carcinoma prognosis is provided, on the other hand, an esophageal squamous cell carcinoma prognosis prediction model is established, so that individual treatment of esophageal squamous cell carcinoma isrealized, the comprehensive treatment level of the esophageal squamous cell carcinoma is improved, the life quality of esophageal squamous cell carcinoma patients is improved, and the lifetime of theesophageal squamous cell carcinoma patients is prolonged.

Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:

The invention discloses a long-chain non-coding RNA marker for assisting diagnosis of esophageal squamous cell carcinoma (ESCC). The long-chain non-coding RNA is LINC01419, the expression amount of the long-chain non-coding RNA is detected and can be used for auxiliary diagnosis or prediction of the esophageal squamous cell carcinoma, and the methylation status of a GSTP1 gene is monitored to predict the sensitivity of the esophageal squamous cell carcinoma to 5-FU chemotherapy. The expression level of a LINC01419 gene can be detected by an RT-PCR, real-time quantitative PCR, immunoassay, in situ hybridization, a chip or a high-throughput sequencing platform. The invention further discloses application of a methyltransferase inhibitor 5-Aza-CdR to regulate the expression of the long-chainnon-coding RNA LINC01419 and response to the 5-FU, and application of an inhibitor medicine including the long-chain non-coding RNA LINC01419 in treatment of the esophageal squamous cell carcinoma. The molecular marker of the esophageal squamous cell carcinoma is provided, a theoretical basis for mechanism research and clinical individualized treatment of the esophageal squamous cell carcinoma isprovided, and by monitoring the overexpression of the LINC01419 in the ESCC, a new treatment strategy for the clinical treatment of the ESCC can be provided.

The invention discloses an esophageal squamous carcinoma radical postoperative patient prognosis prediction model construction method and device, and the method comprises the steps: obtaining clinical diagnosis and treatment data and follow-up visit survival data, carrying out multi-factor Cox regression analysis on patient characteristic variables, tumor pathology characteristic variables, treatment condition variables and test index variables according to follow-up visit survival data, carrying out variable screening by utilizing a step-by-step back algorithm and an Akaike information criterion, and carrying out variable screening on the screened candidate variables again to obtain modeling variables; and performing multi-factor Cox regression analysis on modeling variables and interaction items of every two modeling variables to construct a prognosis prediction model of a patient after the esophageal squamous carcinoma radical operation, wherein the prediction variables comprise age, gender, tumor primary position, T stage, lymph node detection number, tumor size, preoperative hemoglobin level and N stage treatment mode interaction items. According to the method, the prediction accuracy can be improved, the optimal benefit group of different treatment schemes is defined, and the prognosis evaluation precision of the esophageal squamous cell carcinoma is realized.

Methods of genomic screening to identify epigenetically silenced genes, including epigenetically silenced tumor suppressor genes are provided. Also provided are methods of detecting a cancer, for example, an esophageal squamous cell carcinoma or a head and neck squamous cell carcinoma, as are methods of treating a subject having such a cancer.